Results 61 to 70 of about 3,987 (159)

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study

Frontiers in Allergy
IntroductionSevere eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients ...
Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D’Amato   +24 more
doaj   +1 more source

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Therapeutics and Clinical Risk Management, 2018
Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash ...
Maselli DJ, Rogers L, Peters JI
doaj  

Benralizumab in Real Life [PDF]

Journal of Investigational Allergology and Clinical Immunology, 2021
J C, Miralles López, A I, Escudero Pastor, A, Carbonell Martínez, C, Navarro Garrido, Y, Bonilla Pacheco, Y, Petrik Petrik   +5 more
openaire   +2 more sources

Effect of benralizumab treatment on the airway microbiome in COPD

ERJ Open Research
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil ...
Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R. Barer, Christopher McCrae, Christopher E. Brightling   +7 more
doaj   +1 more source

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

Journal of Asthma and Allergy, 2019
J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6 1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung ...
FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, Barker P, Martin UJ   +7 more
doaj  

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Biologics: Targets & Therapy, 2019
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Caminati M, Bagnasco D, Vaia R, Senna G
doaj  

Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis

Clinical and Translational Allergy
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Christiane E. Whetstone, Ruth P. Cusack, Emma L. Price, Karen J. Howie, Caitlin Stevens, Dhuha Al‐Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman, Vanessa Luk, Paul M. O'Byrne, Mark D. Inman, Roma Sehmi, Hermenio Lima, Gail M. Gauvreau   +15 more
doaj   +1 more source

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj  

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab

ACR Open Rheumatology
Objective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler, Nancy Agmon‐Levin, David R. W. Jayne, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Sofia Necander, Anat Shavit, Claire Walton, Peter A. Merkel   +9 more
doaj   +1 more source

Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis

Frontiers in Immunology
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by eosinophilic inflammation and necrotizing vasculitis.
Nanxi Zhou, Chunxiao Fang, Min Feng, Chang Dong   +3 more
doaj   +1 more source